<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170166</url>
  </required_header>
  <id_info>
    <org_study_id>249246</org_study_id>
    <nct_id>NCT04170166</nct_id>
  </id_info>
  <brief_title>Subacromial Injections for Shoulder Subacromial Pain Syndrome - Anterolateral vs Posterior Approach</brief_title>
  <official_title>Subacromial Injections for Shoulder Subacromial Pain Syndrome - Comparing Anterolateral Versus Posterior Approach: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blackpool Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blackpool Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if there is any difference in terms of pain relief in patients&#xD;
      with shoulder subacromial pain syndrome, when given a steroid injection into the subacromial&#xD;
      space via an anterolateral approach compared to a posterior approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who present with subacromial pain syndrome (disorders such as subacromial bursitis,&#xD;
      rotator cuff tendinopathy, calcific tendinitis, subacromial inflammation with a partial&#xD;
      thickness rotator cuff tear) to the orthopaedic outpatient clinic are treated initially with&#xD;
      a subacromial steroid injection in addition to physiotherapy for a period of 3 months. This&#xD;
      applies to patients who have had no other treatments previously as well as to patients who&#xD;
      have had previous physiotherapy or steroid injections prior to presentation. Patients who do&#xD;
      not want to undergo the treatment offered are either treated with simple analgesia, sole&#xD;
      physiotherapy or surgery.&#xD;
&#xD;
      When a patient with one of the above conditions agrees to go ahead with a steroid injection&#xD;
      followed by physiotherapy, the steroid injection is given at the earliest opportunity. The&#xD;
      steroid injection is given into the subacromial space either using the anterolateral&#xD;
      (front-side) approach (1 cm below and behind the anterior edge of the acromion with the&#xD;
      needle aiming towards the under surface of the acromion) or using the posterior (back-side)&#xD;
      approach ( 1cm inferior and medial to the posterlateral acromial edge with the needle&#xD;
      pointing towards the anterolateral aspect of the acromion). The exact approach is determined&#xD;
      according to the preference of the person carrying out the injection. As a routine we use a&#xD;
      10ml syringe containing 10mls of 0.25% Marcaine along with 40mg triamcinolone with an 18&#xD;
      gauge (green) needle. It is normal for patients to complain of some discomfort during the&#xD;
      injection. If a patient experiences any significant discomfort or they cannot tolerate the&#xD;
      injection for whatever reason, then the injection is discontinued and is not reattempted&#xD;
      using a different approach.&#xD;
&#xD;
      Following the injection, patients are questioned on any discomfort experienced during the&#xD;
      injection and on whether or not their pain has improved. They are then taken through a&#xD;
      protocol of physiotherapy for their shoulder over the subsequent 3 months. A protocol is&#xD;
      issued for guidance however therapists are allowed to use other modalities as per their&#xD;
      discretion. The frequency of appointments with physiotherapy will depend on patient's&#xD;
      symptoms as well as their progression. For study purposes a frequency record of these&#xD;
      meetings will be kept and matched to the overall OSS. Patients are seen routinely in 3 months&#xD;
      following an injection in order to assess any improvement in symptomatology using the OSS,&#xD;
      visual analogue score, DASH and SF36 questionaires. If the symptoms have improved then no&#xD;
      further intervention is taken. Further OSS, visual analogue pain score, DASH and SF36&#xD;
      questionaires will be posted out at 6 months and 1 year. On the other hand, if they are still&#xD;
      troubled with symptoms then the possibility of further injections or surgery is discussed.&#xD;
&#xD;
      The aim of this study is to compare the two approaches that are currently used for&#xD;
      subacromial steroid injections, namely the anterolateral and posterior approach, with regards&#xD;
      to their effectiveness in improving shoulder symptoms. There will be no deviation from our&#xD;
      routine protocol other than randomising patients who agree to participate in this study to&#xD;
      either the anterolateral or posterior approach.&#xD;
&#xD;
      In summary, it is patients who are seen in clinic with a subacromial pathology and&#xD;
      subsequently diagnosed with shoulder subacromial pain syndrome, who are offered an injection.&#xD;
      Those who agree to have an injection will then be invited to participate in the study. An&#xD;
      information leaflet will be given to all potential participants and they will be allowed&#xD;
      sufficient time to read through it, digest all the information and ask any questions they may&#xD;
      have before making a decision regarding their participation. Those who agree to participate&#xD;
      will be randomly allocated, using sealed envelopes to one of the two approaches for the&#xD;
      injection. The injection will then be administered via the selected approach by a clinician&#xD;
      who is qualified in carrying out the procedure. Patients will be asked about any discomfort&#xD;
      experienced during the injection, improvement in pain following the injection prior to&#xD;
      leaving hospital and overall satisfaction with the injection. Following this patients will&#xD;
      have physiotherapy as an outpatient as routine and will be seen at about 3 months post&#xD;
      injection for a further assessment at the clinic. Again the shoulder assessment will be&#xD;
      repeated on that occasion. Shoulder assessment questionaires will be posted out for&#xD;
      completion at 6 months and 1 year (OSS, pain on visial analogue scale, DASH and SF36) There&#xD;
      will be no change in patients care from routine practice other than the randomisation of the&#xD;
      approach used for the injection. Patients who are invited to participate in the study and&#xD;
      agree to participate will have their GP informed of their participation.&#xD;
&#xD;
      Assessments&#xD;
&#xD;
        1. Prior to injection: assessment of pain using a visual analogue score, clinical&#xD;
           assessment of shoulder movement and completion of a modified Oxford Shoulder Score,&#xD;
           Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.&#xD;
&#xD;
        2. 20-30 minutes Post injection: assessment of pain using a visual analogue score&#xD;
&#xD;
        3. Prior to leaving hospital: pain experienced during the administration of the injection&#xD;
           and the overall satisfaction with the injection&#xD;
&#xD;
        4. 3 months post injection: assessment of pain using a visual analogue score, clinical&#xD;
           assessment of shoulder movement and completion of a modified Oxford Shoulder Score,&#xD;
           Disabilities of Shoulder, Arm and Hand questionaires and Short Form 36 Health Survey.&#xD;
&#xD;
        5. 6 months and 1 year post injection: assessment of pain using visual analogue score and&#xD;
           completion of a modified Oxford Shoulder Score, Disabilities of Shoulder, Arm and Hand&#xD;
           questionaires and Short Form 36 Health Survey via post.&#xD;
&#xD;
      The main outcome for this study will be the Oxford Shoulder Score (OSS) at 3 months&#xD;
      post-injection. In addition to the standard OSS, the questionnaire will inquire about general&#xD;
      symptoms and signs, duration, hand dominance, previous injuries to the shoulder and previous&#xD;
      treatments to the shoulder. The follow up questionnaire will be identical to the initial&#xD;
      questionnaire but excluding questions on previous treatments, hand dominance, injuries and&#xD;
      duration.&#xD;
&#xD;
      Other demographics that will be recorded on the pre-designed pro forma include: number and&#xD;
      frequency of physiotherapy sessions pre and post injection, and subsequent need for further&#xD;
      management.&#xD;
&#xD;
      Hard copies of data (questionnaires and forms) collected will be placed into the patient's&#xD;
      notes. At the same time this data will be recorded electronically on an Excel database and&#xD;
      saved on an encrypted, password protected memory stick. This memory stick will be stored in a&#xD;
      locked filing cabinet in the orthopaedic department at Blackpool Victoria Hospital. Please&#xD;
      note: The electronic data will contain NO identifiable information. Participants will be&#xD;
      identified by a unique study I.D number which can only be linked to them by members of the&#xD;
      research team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxford Shoulder Score</measure>
    <time_frame>3 months</time_frame>
    <description>The primary outcome measure will be the change in the Oxford Shoulder Score at 3 months post injection. Scores range from 0-48 with 48 being the best possible outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxford Shoulder Score</measure>
    <time_frame>6 months and 1 year</time_frame>
    <description>Change in the Oxford Shoulder Score at 6 months and 1 year post injection. Scores range from 0-48 with 48 being the best possible outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on visual analogue scale</measure>
    <time_frame>3 months, 6 months and 1 year post injection</time_frame>
    <description>Change in pain on the visual analogue scale at 3 months, 6 months and 1 year post injection. As this is a visual analogue scale this is a visual scale with no numeric values attached however on the left side of the scale will be no pain and the right side will be maximal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disabilities of Arm, Shoulder and Hand Questionnaire</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Change in the Disabilities of Arm, Shoulder and Hand Questionnaire score at 3 months, 6 months and 1 year post injection. This is a score that ranges from 0-100 with 0 meaning no disability and 100 meaning most severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Health Survey Score</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
    <description>Change in the Short From 36 Health Survey Score at 3 months, 6 months and 1 year post injection. This is a range from 0-100 with the higher the score, the less disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Shoulder Subacromial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Anterolateral Approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The randomised group of patients receiving the subacromial steroid injection via an anterolateral approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior Approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The randomised group of patients receiving the subacromial steroid injection via a posterior approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anterolateral subacromial steroid injection</intervention_name>
    <description>Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach</description>
    <arm_group_label>Anterolateral Approach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterior subacromial steroid injection</intervention_name>
    <description>Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach</description>
    <arm_group_label>Posterior Approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient diagnosed with shoulder subacromial pain syndrome&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Capacity to give valid consent for participation&#xD;
&#xD;
          -  Able to complete the follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Lacking capacity/unable to give valid consent for participation&#xD;
&#xD;
          -  Full thickness rotator cuff tear diagnosed on either Ultrasound scan or Magnestic&#xD;
             Resonance Imaging&#xD;
&#xD;
          -  Unable to complete follow up&#xD;
&#xD;
          -  Unable to speak or read English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charalambos Charalambous</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Orthopaedic Surgeon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maureen Morgan</last_name>
    <phone>+441253955453</phone>
    <email>maureen.morgan1@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Maureen Morgan</last_name>
      <phone>+441253955453</phone>
      <email>maureen.morgan1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Charalambos Charalambous</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John T Hirst</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blackpool Teaching Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Charalambos Charalambous</investigator_full_name>
    <investigator_title>Consultant Orthopaedic Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT04170166/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

